{
    "clinical_study": {
        "@rank": "127600", 
        "arm_group": {
            "arm_group_label": "Pegasys", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This open-label, single-arm, multicenter study will evaluate the efficacy and safety of\n      adding Pegasys (peginterferon alfa-2a) to nucleos(t)ide analogue (NAs) treatment in patients\n      with HBeAg-negative chronic hepatitis B genotype D showing stable HBV DNA suppression. After\n      a 12-week Lead-in period on treatment with NA, patients with a HBsAg decline <0.5 log10\n      IU/ml will enter the Add-on period to receive Pegasys 180 mcg subcutaneously weekly for 48\n      weeks in addition to their current NA treatment. Follow-up will be a further 48 weeks,\n      during which the patients will continue their NA treatment."
        }, 
        "brief_title": "A Study of Pegasys (Peginterferon Alfa-2a) Added to Nucleos(t)Ide Analogue Treatment in Patients With HBeAg-Negative Chronic Hepatitis B Genotype D Showing Stable HBV DNA Suppression", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis B, Chronic", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B", 
                "Hepatitis, Chronic", 
                "Hepatitis B, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, 18 - 65 years of age\n\n          -  Chronic hepatitis B\n\n          -  Negative for HBeAg\n\n          -  On monotherapy with any nucleos(t)ide analogue (NA) but telbivudine at enrolment, and\n             HBV DNA persistently below 20 IU/ml for at least 12 months\n\n          -  HBsAg >100 IU/ml at the beginning of the Lead-in phase, confirmed before addition of\n             Pegasys\n\n          -  Showing a steady HBsAg kinetic (HBsAg decrease <0.5 log10 IU/ml from Week -12 to\n             start of the Add-on phase)\n\n          -  Negative pregnancy test for women of childbearing potential\n\n          -  Women of childbearing potential and fertile males with female partners of\n             childbearing potential must be using reliable contraception during and for 3 months\n             after the Add-on phase\n\n        Exclusion Criteria:\n\n          -  Coinfection with HAV, HCV, HDV, HIV\n\n          -  Evidence of decompensated liver disease (Child-Pugh >/=6)\n\n          -  History or other evidence of a medical condition associated with chronic liver\n             disease (e.g. hemochromatosis, autoimmune hepatitis, alcoholic liver disease, toxin\n             exposure)\n\n          -  Known hypersensitivity to peginterferon alfa-2a\n\n          -  Pregnant of breastfeeding women\n\n          -  Evidence of alcohol and/or drug abuse\n\n          -  History of severe psychiatric disease, especially depression\n\n          -  History of immunologically mediated disease\n\n          -  History or evidence of bleeding from esophageal varices or other conditions\n             consistent with decompensated liver disease\n\n          -  History or evidence of severe pulmonary disease associated with functional\n             limitations\n\n          -  History of severe cardiac disease\n\n          -  History of severe seizure disorder or current anticonvulsant use\n\n          -  Evidence of an active or suspected cancer or a history of malignancy (other than\n             basocellular carcinoma or in situ cervical carcinoma) within 5 years prior to study\n             entry\n\n          -  History of having received any systemic anti-neoplastic (including radiation) or\n             immunomodulatory  (including systemic corticosteroids) treatment </= 6 months prior\n             to the first dose or the expectation that such a treatment will be needed at any time\n             during the study\n\n          -  History or other evidence of severe retinopathy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01706575", 
            "org_study_id": "ML28262", 
            "secondary_id": "2012-000080-25"
        }, 
        "intervention": [
            {
                "arm_group_label": "Pegasys", 
                "description": "180 mcg subcutaneously weekly, 48 weeks", 
                "intervention_name": "peginterferon alfa-2a [Pegasys]", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Pegasys", 
                "description": "Adenovir, entecavir, lamivudine or tenofovir", 
                "intervention_name": "nucleos(t)ide analogues", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Peginterferon alfa-2a", 
                "Interferon-alpha"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Napoli", 
                        "country": "Italy", 
                        "state": "Campania", 
                        "zip": "80131"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bologna", 
                        "country": "Italy", 
                        "state": "Emilia-Romagna", 
                        "zip": "40138"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Udine", 
                        "country": "Italy", 
                        "state": "Friuli-Venezia Giulia", 
                        "zip": "33100"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Roma", 
                        "country": "Italy", 
                        "state": "Lazio", 
                        "zip": "00133"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Roma", 
                        "country": "Italy", 
                        "state": "Lazio", 
                        "zip": "00161"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Genova", 
                        "country": "Italy", 
                        "state": "Liguria", 
                        "zip": "16132"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy", 
                        "state": "Lombardia", 
                        "zip": "20122"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Torino", 
                        "country": "Italy", 
                        "state": "Piemonte", 
                        "zip": "10126"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Foggia", 
                        "country": "Italy", 
                        "state": "Puglia", 
                        "zip": "71100"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cagliari", 
                        "country": "Italy", 
                        "state": "Sardegna", 
                        "zip": "09042"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Messina", 
                        "country": "Italy", 
                        "state": "Sicilia", 
                        "zip": "98124"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Palermo", 
                        "country": "Italy", 
                        "state": "Sicilia", 
                        "zip": "90127"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pisa", 
                        "country": "Italy", 
                        "state": "Toscana", 
                        "zip": "56124"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Padova", 
                        "country": "Italy", 
                        "state": "Veneto", 
                        "zip": "35128"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase IIb, Open Label, Single Arm, Multicenter Study to Evaluate the Effect of 48-weeks PEG-Interferon Alfa-2a (PEG-IFN) Administration on Serum HBsAg in Chronic Hepatitis B, HBeAg-Negative, Genotype D Patients on Treatment With Nucleos(t)Ide Analogues (NAs), Showing Stable HBV DNA Suppression", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Italy: Agenzia Italiana del Farmaco (AIFA)"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Proportion of patients with serum HBsAg decrease >/= 50% from baseline to the end of the combination treatment Pegasys plus NA (Study Week 48)", 
            "safety_issue": "No", 
            "time_frame": "approximately 2.5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01706575"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Proportion of patients with HBsAg decrease >/=1 log10 IU/ml from baseline to Week 48", 
                "safety_issue": "No", 
                "time_frame": "approximately 2.5 years"
            }, 
            {
                "measure": "Change in HBsAg levels", 
                "safety_issue": "No", 
                "time_frame": "from baseline to Week 96"
            }, 
            {
                "measure": "Proportion of patients with HBsAg </= 0.05 UI/ml at Week  48", 
                "safety_issue": "No", 
                "time_frame": "approximately 2.5 years"
            }, 
            {
                "measure": "Proportion of patients with HBsAg </= 0.05 UI/ml at Week 72", 
                "safety_issue": "No", 
                "time_frame": "approximately 2.5 years"
            }, 
            {
                "measure": "Proportion of patients with HBsAg </= 0.05 UI/ml at Week 96", 
                "safety_issue": "No", 
                "time_frame": "approximately 2.5 years"
            }, 
            {
                "measure": "HBsAg levels according to IL28B genotypes", 
                "safety_issue": "No", 
                "time_frame": "approximately 2.5 years"
            }, 
            {
                "measure": "HBsAg levels according to IP-10 serum levels", 
                "safety_issue": "No", 
                "time_frame": "approximately 2.5 years"
            }, 
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "approximately 2.5 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}